Jed Latkin, CEO, COO & CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 5,000 shares at $1.08 ($5K) on 2020-02-20, disclosed to the SEC on 2020-02-20.
Open-market purchase of $5k NAVB by CEO, COO & CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| NAVB | BUY | 2019-05-15 | $10K | — | Filing → |
| NAVB | BUY | 2017-05-31 | $3K | — | Filing → |
| NAVB | BUY | 2017-05-23 | $11K | — | Filing → |